Back to search

Article

Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.

2021-06-03

Abstract excerpt

<title>Abstract</title> <p>Cerebral venous thrombosis was reported as a rare but serious adverse event in young and middle-aged vaccinees following immunization with AstraZeneca’s ChAdOx1-nCov-19 vaccine. As a consequence, several European governments recommended using this vaccine only in individuals older than 60 years leaving millions of ChAd primed individuals with the decision to either receive a second shot...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7e414204-500c-511c-97c1-4d37e0764ec4
DOI
10.21203/rs.3.rs-580444/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.DOI 10.21203/rs.3.rs-580444/v1
Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccinationSemantic proximity
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccinationSemantic proximity
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variantsSemantic proximity
Immunogenicity and efficacy of heterologous ChAdOx1–BNT162b2 vaccinationSemantic proximity
Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2Semantic proximity
Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccinationSemantic proximity
BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19Semantic proximity
Immunogenic Dynamics and SARS-CoV-2 Variants Neutralization of the Heterologous ChAdOx1-S/BNT162b2 Vaccination: Secondary Analysis of the CombiVacS StudySemantic proximity
Thrombosis of Transverse Cerebral Venous Sinus Secondary to Vaccine ChAdOx1-S (Recombinant) First Report in SouthamericaSemantic proximity
COVID-19 vaccine-associated cerebral venous thrombosis in GermanySemantic proximity
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adultsSemantic proximity
Effect of a COVID-19-Heterologous Vaccination Schedule on Haemostasis: A Subanalysis of the Phase 2, Multicentre, Randomised, Controlled CombiVacS StudySemantic proximity
Select a neighboring publication to make it the new centre.